History and Global Brand
Since 1878, we have been harnessing the full potential of science to treat challenging human diseases. Our discoveries have led to new treatment options that have improved the lives of patients worldwide. Throughout our history, we have remained true to our founding principle — to supply the best possible medicines to protect the health and well-being of the patients we serve.
Our Journey
1878 – The Founding
1886 – Acquiring Western Medicines
1910 – Construction of First Manufacturing Plant
Early 1910s – First Steps in Product Development & Fighting Infectious Disease
1950s – Global Contributions and First Partnerships
Beginning with our own research and development in infectious disease, we introduced Sinomin, a sulfonamide antibiotic, in 1959 and soon out-licensed it to Roche. The antibiotic circulated worldwide, becoming an instrumental tool in the fight against infectious diseases. This period also marked the beginning of our collaboration with other global pharmaceutical companies, including Eli Lilly and Company.
1980s – Growth and Specialization
2001 – United States Expansion
2008 – Acquisitions and Further Success
2010s – Drug Discovery and Continued Growth
2020s – Advancing Science and Expanding Global Presence
A Legacy in Infectious Disease
Since 1953, Shionogi has been a leader in infectious disease discovery and commercialization.
1953
ERYTHROMYCIN – was licensed in Japan1959
SULFAMETHOXAZOLE – a sulfa antibiotic used to treat bacterial infections1970
CEPHALEXIN – a first-generation cephalosporin1976
SULFAMETHOXAZOLE/TRIMETHOPRIM1981
VANCOMYCIN – a Gram-positive anti-MRSA1982
LATAMOXEF/MOXALACTAM – the first of two globally approved oxacephems CEFACLOR – a second-generation cephalosporin1984
CEFAMANDOLE – a second-generation cephalosporin1988
FLOMOXEF – the second of two globally approved oxacephems1992
CEFTIBUTEN – a third-generation oral cephalosporin antibiotic1993
CEFPIROME – a fourth-generation cephalosporin1997
CEFCAPENE – a third-generation oral cephalosporin antibiotic2005
DORIPENEM – a carbapenem antibiotic2010
PERAMIVIR – an antiviral for influenza2013
DOLUTEGRAVIR – an HIV integrase inhibitor2018
BALOXAVIR MARBOXIL – antiviral drug2019
CEFIDEROCOL – cephalosporin for certain Gram-negative infections2022
ENSITRELVIR – an investigational oral antiviral for COVID-192023
XERUBORBACTAM – an investigational β-lactamase inhibitorKey
Commercialized by Shionogi Discovered and commercialized by ShionogiOur Global Brand
Our corporate logo is derived from the “fundoh,” a stylized image of a balance weight traditionally used to weigh medicine on a scale. The fundoh also symbolizes “accuracy,” “honesty,” and “trust” and represents precision and our commitment to quality.
Capability and Vision, Unified
"Trust" and "Accuracy."
Dynamic expression and unity.
Designed to give a sense of trust and security.